Cargando…

Screening New Blood Indicators for Non-alcoholic Fatty Liver Disease (NAFLD) Diagnosis of Chinese Based on Machine Learning

BACKGROUND: The prevalence of NAFLD is increasing annually. The early diagnosis and control are crucial for the disease. Currently, metabolic indicators are always used clinically as an auxiliary diagnosis of NAFLD. However, the prevalence of NAFLD is not only increased in obese/metabolic-disordered...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Cheng, Yan, Junbin, Zhang, Shuo, Xie, Yiwen, Nie, Yunmeng, Chen, Zhiyun, Xu, Sumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218755/ https://www.ncbi.nlm.nih.gov/pubmed/35755070 http://dx.doi.org/10.3389/fmed.2022.771219

Ejemplares similares

Natural Compounds: A Potential Treatment for Alcoholic Liver Disease?
por: Yan, Junbin, et al.
Publicado: (2021)

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
por: Parameswaran, Madhangi, et al.
Publicado: (2021)

The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases
por: Yan, Junbin, et al.
Publicado: (2021)

Exploring and Verifying the Mechanism and Targets of Shenqi Pill in the Treatment of Nonalcoholic Steatohepatitis via Network Pharmacology and Experiments
por: He, Beihui, et al.
Publicado: (2022)

A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)
por: Fu, Clarissa Elysia, et al.
Publicado: (2022)

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Saudi Arabia: Systematic Review and Meta-analysis
por: Alenezi, Yusef M, et al.
Publicado: (2023)

The IDI1/SREBP2 axis drives intrahepatic cholestasis and is a treatment target of San-Huang-Cai-Zhu formula identified by sequencing and experiments
por: Yan, Junbin, et al.
Publicado: (2023)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

Dietary Quality Indices and Biochemical Parameters Among Patients With Non Alcoholic Fatty Liver Disease (NAFLD)
por: Hashemi kani, Ali, et al.
Publicado: (2013)

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kanuri, Giridhar, et al.
Publicado: (2013)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Carneros, David, et al.
Publicado: (2020)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2023)

Simple surrogate equations to predict controlled attenuation parameter values for screening non-alcoholic fatty liver disease in a Chinese population
por: Liu, Hanying, et al.
Publicado: (2022)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
por: Koralegedara, Iresha Sandamali, et al.
Publicado: (2022)

Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort
por: Niederseer, David, et al.
Publicado: (2020)

Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning
por: Cao, Yang, et al.
Publicado: (2023)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Savic, Dragana, et al.
Publicado: (2020)

Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
por: de Carvalho, Sylene Coutinho Rampche, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?
por: Longato, Lisa
Publicado: (2013)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
por: Bramante, Carolyn T., et al.
Publicado: (2020)

The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Maciejewska-Markiewicz, Dominika, et al.
Publicado: (2021)

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
por: Tripodi, Armando, et al.
Publicado: (2022)

Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
por: Yao, Pengyu, et al.
Publicado: (2022)

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
por: Moghtadaie, Atie, et al.
Publicado: (2023)

Association Between Leukocyte Mitochondrial DNA Copy Number and Non-alcoholic Fatty Liver Disease in a Chinese Population Is Mediated by 8-Oxo-2′-Deoxyguanosine
por: Ma, Chifa, et al.
Publicado: (2020)

Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients
por: Damjanovska, Sofi, et al.
Publicado: (2022)

Hypoxia and Non-alcoholic Fatty Liver Disease
por: Isaza, Stephania C., et al.
Publicado: (2020)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
por: Idalsoaga, Francisco, et al.
Publicado: (2020)

Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III
por: Carrillo-Larco, Rodrigo M, et al.
Publicado: (2022)

The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
por: Liu, Qing, et al.
Publicado: (2010)

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
por: Cicero, Arrigo F. G., et al.
Publicado: (2018)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

Macrophages and scavenger receptors in obesity‐associated non‐alcoholic liver fatty disease (NAFLD)
por: Kragh Petersen, Sine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_clgi1dov5n309u1q6uo378ih84